Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway

Chen Lin(Fudan University Shanghai Cancer Center), Jianhua Chang(Shanghai Medical College of Fudan University)
Oncotarget
August 1, 2016
10.18632/oncotarget.10985
Cited by 55

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells
|International Journal of Molecular Medicine|2018|57
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers
|The Oncologist|2022|15